Aptus Pharma

Why is Aptus Pharma Ltd falling/rising?

As of 18-Jul, Aptus Pharma Ltd's stock price is at 240.60, down 3.51% today after an initial gain. Despite strong growth over the past month, today's trading shows profit-taking and reduced investor engagement, contributing to the decline.

As of 18-Jul, Aptus Pharma Ltd's stock price is currently at 240.60, reflecting a decline of 8.75 points, or 3.51%. Despite a strong performance over the past week and month, where the stock rose by 7.41% and 13.57% respectively, today's trading indicates a downturn. The stock opened with a gain of 3.83% but has since fallen, reaching an intraday low of Rs 238.25, which represents a decrease of 4.45% from its high.<BR><BR>The performance today has underperformed the sector by 2.44%, suggesting that while the stock had a positive start, it could not maintain momentum. Additionally, the weighted average price indicates that more volume was traded closer to the low price, which may signal a lack of buying interest at higher levels. Furthermore, there has been a decline in investor participation, with delivery volume falling by 3.77% against the 5-day average, which could contribute to the stock's downward pressure. <BR><BR>Overall, while Aptus Pharma Ltd has shown significant growth year-to-date with a remarkable increase of 254.87%, the current trading session reflects a combination of profit-taking and reduced investor engagement, leading to the observed decline in stock price.

Which are the latest news on Aptus Pharma?

What does Aptus Pharma do?

Aptus Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 394 Cr. It has no reported net sales or profit for the latest quarter, a P/E ratio of 84.00, and a return on equity of 21.29%.

Overview:<BR>Aptus Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Details regarding the incorporation year and any status changes are not available. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 394 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 84.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.28<BR>Return on Equity: 21.29%<BR>Price-to-Book: 18.14<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Aptus Pharma?

Aptus Pharma's peers include Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Valiant Laborato, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma. Key insights show Bafna Pharma has the highest 1-year return at 135.40%, while Medicamen Biotec has the lowest at -46.53%.

Peers: The peers of Aptus Pharma are Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Valiant Laborato, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma and Medico Remedies, while Average management risk is found at Haleos Labs Limi, Albert David, Transchem, and Medicamen Biotec, and the rest have Below Average management risk. Growth is Good at Valiant Laborato, while Below Average growth is seen at Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma. Excellent capital structure is noted at Jenburkt Pharma, Albert David, and Medicamen Biotec, while Good capital structure is seen at Bafna Pharma and Medico Remedies, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma at 135.40%, while Medicamen Biotec has the lowest at -46.53%. Aptus Pharma's 1-year return is not available for comparison. Additionally, peers with negative six-month returns include Haleos Labs Limi, Albert David, Valiant Laborato, Medico Remedies, and Medicamen Biotec.

What is the bonus history of Aptus Pharma?

Aptus Pharma recently announced a 3:2 bonus issue, with an ex-date of May 12, 2026. Shareholders on record by this date will receive 3 additional shares for every 2 shares they currently hold.

Aptus Pharma has a recent bonus issue where they announced a 3:2 bonus. The ex-date for this bonus is set for May 12, 2026. This means that shareholders on record as of this date will receive additional shares in the ratio of 3 shares for every 2 shares they currently hold.